Lion Biotechnologies

Lion Biotechnologies

LOS ANGELES, CA, April 7, 2014 (GLOBE NEWSWIRE)  –Lion Biotechnologies, Inc. (OTCBB: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at … Continue reading
Author: Beyond
Posted: April 7, 2014, 9:31 pm
LOS ANGELES, March 21, 2014 (GLOBE NEWSWIRE) — Lion Biotechnologies, Inc. (OTCQB: LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., … Continue reading
Author: Beyond
Posted: March 21, 2014, 5:58 pm
LOS ANGELES, March 4, 2014 — Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5.  The conference … Continue reading
Author: Lion Biotechnologies
Posted: March 4, 2014, 6:48 pm
LOS ANGELES, January 13, 2014 — Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific.  The conference is being held at the … Continue reading
Author: Lion Biotechnologies
Posted: January 13, 2014, 1:00 pm
Lion Biotechnologies, Inc. (OTC Markets:LBIO) has completed a previously announced private financing with institutional and other accredited investors for gross proceeds of $23.3 million. After paying the placement agent fees and estimated offering expenses payable by the Company, Lion Biotechnologies received net proceeds of approximately $21.6 million. Continue reading
Author: Lion Biotechnologies
Posted: November 6, 2013, 3:00 pm
LOS ANGELES--(BUSINESS WIRE)-- Lion Biotechnologies, Inc. (OTC Markets:LBIO) today announced that it has entered into definitive agreements with institutional and other accredited investors to raise approximately $23 million in a private financing. Subscribers have agreed to purchase units consisting of either (i) one share of common stock and a warrant to purchase a share of common stock, or (ii) one share of the newly authorized Series A Convertible Preferred Stock and a warrant to purchase the number of shares of common stock initially issuable upon the conversion of the preferred stock. Continue reading
Author: Lion Biotechnologies
Posted: October 31, 2013, 3:00 pm
LOS ANGELES--(BUSINESS WIRE)-- Lion Biotechnologies, Inc. (OTC Markets:LBIO) announced that it will begin trading under the ticker symbol ‘LBIO' on the OTC Markets as of the opening of the market today. The new ticker reflects the Company name change from Genesis Biopharma, Inc. announced on 9/25/2013. Continue reading
Author: Lion Biotechnologies
Posted: October 23, 2013, 3:00 pm
LOS ANGELES--(BUSINESS WIRE)-- Lion Biotechnologies, Inc. (OTCBB:GNBPD) today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 12th Annual BIO Investor Forum on Wednesday, October 9, 2013, at 3:00 p.m. Pacific. Continue reading
Author: Lion Biotechnologies
Posted: October 7, 2013, 3:35 pm
LOS ANGELES--(BUSINESS WIRE)-- Lion Biotechnologies, Inc. (OTCBB:GNBPD) is providing updated results from a Phase II trial for metastatic melanoma conducted by the National Cancer Institute (NCI) utilizing the tumor-infiltrating lymphocyte (TIL) technology currently licensed by the Company and being developed under a Cooperative Research and Development Agreement (CRADA) with the NCI. Continue reading
Author: Lion Biotechnologies
Posted: September 30, 2013, 3:41 pm
LOS ANGELES--(BUSINESS WIRE)-- Lion Biotechnologies, Inc. (OTCBB:GNBPD) today announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 3rd Annual LD Micro Invitational investor conference on Wednesday, October 2, 2013, at 4:30 p.m. Pacific. Continue reading
Author: Lion Biotechnologies
Posted: September 27, 2013, 3:43 pm